ScholarLens Back to search
2022•Value in HealthOpen access

EE129 Cost-Effectiveness of Ofatumumab Versus Ocrelizumab in Patients With Active Relapsing Multiple Sclerosis in Portugal

N Gonçalves, J. Esparteiro, Mariana Moreira Machado, C Ferreira, Teresa Guerreiro

Open full text 1 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ocrelizumab, Ofatumumab, Medicine, Multiple sclerosis, Relapsing remitting, CD20, Internal medicine, Fingolimod

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
EE129 Cost-Effectiveness of Ofatumumab Versus Ocrelizumab in Patients With Active Relapsing Multiple Sclerosis in Portugal — Research Paper | ScholarLens